Table S1 from Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances anti-tumour immunity
Andrew A. Guirguis(Peter MacCallum Cancer Centre), Mark A. Dawson(The University of Melbourne), Brian Liddicoat(Broad Institute), Ali Motazedian(Peter MacCallum Cancer Centre), Kathy Knezevic(Peter MacCallum Cancer Centre), Yih-Chih Chan(The University of Melbourne), Claire J. Saunders(Mission Therapeutics (United Kingdom)), Dane Vassiliadis(The University of Melbourne), David Hardick(Mission Therapeutics (United Kingdom)), Byron Andrews(Mission Therapeutics (United Kingdom)), Aleksandra Azevedo(Mission Therapeutics (United Kingdom)), Kevin Tran(Peter MacCallum Cancer Centre), Wesley Blackaby(Mission Therapeutics (United Kingdom)), Joanna Obacz(Immodulon Therapeutics (United Kingdom)), Georgia Tsagkogeorga(Mission Therapeutics (United Kingdom)), Oliver Rausch(Mission Therapeutics (United Kingdom)), Marie Carkill(Charles River Laboratories (United Kingdom)), Andrea Gillespie(National Institutes of Health), Ewa S. Pilka(Evotec (United Kingdom)), Michael E. Harbour(Mission Therapeutics (United Kingdom)), Yaara Ofir-Rosenfeld(Mission Therapeutics (United Kingdom)), Mark R. Albertella(Mission Therapeutics (United Kingdom)), Elanor N. Wainwright(Peter MacCallum Cancer Centre), Benjamin J. Blyth(Peter MacCallum Cancer Centre), Lina Vasiliauskaitė(Mission Therapeutics (United Kingdom)), Enid YN. Lam, Laura MacPherson(Natural Resources Canada)
Cited by 0
Related Papers
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
|Cancer Cell|2019|630
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
|New England Journal of Medicine|2018|429